- Process for the Preparation of Intermediates of Rosiglitazone, Rosiglitazone and New Polymorphic Forms Thereof
-
The invention relates to a polymorphic form of 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzylidene)-2,4-thiazolidinedione (Formula (I)): to a process for its preparation and to the use of such compound for preparing rosiglitazone in the form of a free base or a salt thereof. The invention also relates to a polymorphic form of rosiglitazone in the form of a free base, to a process for its preparation and to the use of such polymorph for preparing a salt of rosiglitazone. The invention also relates to a process of preparing a polymorphic form of a rosiglitazone salt.
- -
-
Page/Page column 5-6
(2009/09/28)
-
- PREPARATION OF ROSIGLITAZONE AND ITS SALTS
-
The present invention relates to rosiglitazone and its pharmaceutically acceptable salts free of at least one of the process related impurities, in particular the dehydro and the succinic acid impurities of rosiglitazone, wherein said impurities are present in an amount of about 05 mg to not more than about 15 mg, and processes for their preparation.
- -
-
Page/Page column 8-9
(2008/06/13)
-
- A PROCESS FOR THE CRYSTALLIZATION OF ROSIGLITAZONE AND ITS DERIVATIVES FROM MIXED SOLVENTS
-
Crystallization of rosiglitazone of formula (I), its penultimate of formula (II), or salts with acids of formula (III), wherein HX stands for a mineral or carboxylic acid, is carried out from mixed organic solvents, consisting of mixtures of carboxylic acids, particularly formic acid, acetic acid or propionic acid, with aliphatic alcohols, particularly methanol, ethanol, 1-propanol, 2- propanol, butanols or amyl alcohols.
- -
-
Page/Page column 20
(2008/06/13)
-
- NEW POLYMORPHOUS FORM OF ROSIGLITAZONE MALEATE
-
A new polymorphous crystalline form of rosiglitazone maleate, called form V, and the methods for obtaining it are described and characterized. Rosiglitazone maleate may be obtained in the form of the single polymorph V by mixing an approximately equimolar mixture of rosiglitazone base and maleic acid into a mixture of alcohols and water, heating the mixture under reflux and subsequently cooling it to ambient temperature.
- -
-
Page/Page column 4-5
(2008/06/13)
-
- PROCESS
-
The present invention relates to processes for the preparation of rosiglitazone, rosiglitazone prepared thereby and pharmaceutical compositions and therapeutic uses thereof, and methods of treatment employing the same.
- -
-
Page/Page column 15
(2008/06/13)
-
- PROCESS FOR PREPARING THIAZOLIDINEDIONES
-
This invention provides a process for reducing an exocyclic double bond at the 5-position of a thiazolidinedione moiety of a thiazolidinedione precursor comprising the steps of: a) preparing a solution or suspension of the thiazolidinedione precursor in a non-ether solvent medium with a base, and b) combining the solution or suspension with a dithionite source. Preferred solvent media include aqueous N,N-dimethylformamide. Sodium dithionite is a preferred dithionite source. In particular the application discloses preparation processes for Pioglitazone, Rosilitazone and Troglitazone.
- -
-
Page/Page column 15
(2008/06/13)
-
- NOVEL CO-PRECIPITATE
-
A novel coprecipitate of amorphous rosiglitazone maleate with a pharmaceutically acceptable carrier, e.g. polyvinylpyrolidone, mannitol, lactose, methylcellulose, cyclodextrin or silicon dioxide, a process for the preparation of said novel co-precipitate and the use of said novel coprecipitate of amorphous rosiglitazone with a pharmaceutically acceptable carrier in the treatment and / or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, are disclosed. A novel solid solution of rosiglitazone maleate with a pharmaceutically acceptable carrier, preferably with polyethyelene glycol PEG from 4000 to 40.000 of average mol. wt., a process for the preparation thereof and use are disclosed. A novel coprecipitate of amorphous rosiglitazone maleate with a pharmaceutically acceptable carrier and a novel solid solution of rosiglitazone maleate with a pharmaceutically acceptable inert carrier are stable and may be particularly suitable for bulk preparation, handling and formulation advantages.
- -
-
Page/Page column 16
(2008/06/13)
-
- A PROCESS FOR PURIFICATION
-
The present invention provides a process for purification of pharmaceutically active compounds selected from the group consisting of thiazolidinedione derivatives and trans-3-Ethyl-2,5-dihydro-4-methyl-N- [2-[4-[[[[(4-methylcyclohexyl)amino] carbonyl] amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide comprising extraction in a solvent comprising an alkanol (C1-C4) and ammonia.
- -
-
Page/Page column 13-14
(2010/02/12)
-
- AMORPHOUS FORM OF ROSIGLITAZONE MALEATE AND PROCESS FOR PREPARATION THEREOF
-
An amorphous rosiglitazone maleate and its preparation as well as uses thereof for a pharmaceutical composition and a method for medical treatment including combination therapy are described.
- -
-
Page/Page column 17
(2008/06/13)
-
- Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
-
This invention relates to novel polymorphic/pseudopolymorphic forms of 5-[4-[2[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate having formula (I). The invention also relates to a pharmaceutical composition comprising the novel polymorphic form or their mixture and a pharmaceutically acceptable carrier. The polymorphic forms of the present invention are more active, as antidiabetic agent, than the hitherto known 5-[4-[2-[N-(2-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate.
- -
-
-
- Polymorphous forms of rosiglitazone maleate
-
Three new polymorphous crystalline forms of rosiglitazone maleate, termed respectively form I, II and III and the methods for selectively obtaining each form are described and characterized. Rosiglitazone maleate may be obtained in the form of the single polymorph I by blending an approximately equimolar mixture of rosiglitazone base and maleic acid in a series of solvents and mixtures thereof which comprises isopropanol, acetone, ethyl acetate, isopropyl acetate, THF, followed by cooling of the mixture to ambient temperature; the form II may on the other hand be obtained by means of treatment of the approximately equimolar mixture of rosiglitazone base and maleic acid in water under reflux, followed by cooling of the mixture to ambient temperature; the polymorph III may be obtained by treating a mixture of rosiglitazone base with a double molar quantity of maleic acid in ethanolic solvents.
- -
-
-
- PROCESS FOR PREPARING A POLYMORPH OF ROSIGLITAZONE MALEATE
-
A crystallisation process for preparing a polymorph of rosiglitazone maleate (Compound 1), and a process for preparing Compound 1 with a polymorphic purity that is suitable for use as a seed material in a crystallisation process for preparing Compound 1.
- -
-
-
- Process for the preparation of pyridine derivative
-
The invention discloses a process for the preparation of a pyridine derivative namely 5-{4-2(N-methyl-N(2-pyridyl) amino ethoxy]benzyl]thiazolidine-2,4-dione maleate comprising the steps of: (a) reacting 2-chloropyridine with 2-(N-methyl amino) ethanol; (b) coupling 2-N-methyl-N-(2-pyridyl)amino)ethanol) obtained in step (a) and 4-fluorobenzaldehyde in an aprotic polar solvent with an alkali metal hydroxide or an alkali metal alkoxide as base. (c) isolating the product of the coupling reaction viz 4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzaldehyde; (d) converting said isolated benzaldehyde compound of step (c) into 5-[4-[2-N-methyl-N-(2-pyridyl) amino)ethoxy]benzyl]thiazolidine-2,4-dione in a known manner and (e) converting said thiazolidine-2,4-dione compound obtained in step (d) into a pharmaceutically acceptable maleate salt.
- -
-
-
- Substituted thiazolidinedionle derivatives
-
STR1 A compound of formula (I) or a tautomeric form therof and/or a pharmaceutically acceptable solvate thereof, wherein R1,A1,A2,M are as defined in the, specification. A process for preparing such a compound, a pharmaceutical composition containin such a compound and the use of such a compound for treating hyperglycemia.
- -
-
-
